New horizons of methotrexate application

Vladimir Maksimovic; Svetlana Golocorbin-Kon; Momir Mikov; Jelena Cvejic; Zora Pavlovic Popovic; Sasa Vukmirovic

doi:10.5937/pomc17-24188

Vladimir Maksimovic Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Serbia
Svetlana Golocorbin-Kon Department of Pharmacy, Faculty of Medicine, University of Novi Sad, Serbia
Momir Mikov Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Serbia
Jelena Cvejic Department of Pharmacy, Faculty of Medicine, University of Novi Sad, Serbia
Zora Pavlovic Popovic Institute of Pulmonary Diseases, Sremska Kamenica Faculty of Medicine, University of Novi Sad, Serbia Corresponding author:
Sasa Vukmirovic Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Serbia

DOI: https://doi.org/10.5937/pomc17-24188

Abstract

Methotrexate is an anti-inflammatory and anticancer drug that has been used in the treatment of various oncological and inflammatory diseases (such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, sarcoidosis, etc.). Scientists are working on finding optimal formulation that will maintain its efficacy and improve safety and nanoparticles have shown to be carriers with great potential as they protect the drug from degradation while at the same time they increase absorption. In vivo and in vitro studies of numerous nanoparticle preparations have showed that they generally have appropriate characteristics and can be carriers for targeted delivery of methotrexate to the tissues affected by disease. Topical preparations of methotrexate, mainly for the treatment of psoriasis, have also been assessed in various research and have showed promising results. Further research is warranted by the obtained results and will hopefully lead to new methotrexate formulations that will be approved by regulatory authorities and used instead of existing ones to improve efficacy of the drug and patients’ safety.

Author Biographies

Vladimir Maksimovic, Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Serbia

PhD student

Svetlana Golocorbin-Kon, Department of Pharmacy, Faculty of Medicine, University of Novi Sad, Serbia

Professor

Momir Mikov, Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Serbia

Full Professor

Jelena Cvejic, Department of Pharmacy, Faculty of Medicine, University of Novi Sad, Serbia

Full Professor

Zora Pavlovic Popovic, Institute of Pulmonary Diseases, Sremska Kamenica Faculty of Medicine, University of Novi Sad, Serbia Corresponding author:

Physician, Professor

Sasa Vukmirovic, Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Serbia

Professor

References

Neradil J, Pavlasova G, Veselska R. New mechanisms for an old drug; DHFR- and non-DHFR-mediated effects of methotrexate in cancer cells. Klin Onkol. 2012;25 Suppl 2:2S87-92.

Chen G, Fawcett JP, Mikov M, Tucker IG. Simultaneous determination of methotrexate and its polyglutamate metabolites in Caco-2 cells by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2009;50:262-6.

Montesinos MC, Takedachi M, Thompson LF, Wilder TF, Fernández P, Cronstein BN. The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5'-nucleotidase: findings in a study of ecto-5'-nucleotidase gene-deficient mice. Arthritis Rheum. 2007;56:1440-5.

Haskó G, Cronstein B. Regulation of inflammation by adenosine. Front Immunol. 2013;4:85.

Vergne P et al. Methotrexate and cyclooxygenase metabolism in cultured human rheumatoid synoviocytes. J Rheumatol. 1998;25:433-40.

Sperling RI, Benincaso AI, Anderson RJ, Coblyn JS, Austen KF, Weinblatt ME. Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis Rheum. 1992;35:376-84.

Weinblatt ME. Methotrexate in Rheumatoid Arthritis: A Quarter Century of Development. Trans Am Clin Climatol Assoc. 2013;124:16–25.

Nemati S, Teimourian S. An Overview of Inflammatory Bowel Disease: General Consideration and Genetic Screening Approach in Diagnosis of Early Onset Subsets. Middle East J Dig Dis. 2017;9:69–80.

Fakhoury M, Negrulj R, Mooranian A, Al-Salami H. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res. 2014;7:113–20.

Herfarth HH, Kappelman MD, Long MD, Isaacs KL. Use of methotrexate in the treatment of inflammatory bowel diseases (IBD). Inflamm Bowel Dis. 2016;22:224–33.

Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R. Methotrexate: an old new drug in autoimmune disease. Expert Rev Clin Immunol. 2014;10:1519-30.

Kim BR, Ohn J, Choi CW, Youn SW. Methotrexate in a Real-World Psoriasis Treatment: Is It Really a Dangerous Medication for All? Ann Dermatol. 2017;29:346–8.

Soto-Gomez N, Peters JI, Nambiar AM. Diagnosis and Management of Sarcoidosis. Am Fam Physician. 2016;93:840-8.

Baughman RP, Lower EE. A clinical approach to the use of methotrexate for sarcoidosis. Thorax. 1999;54:742–6.

Jang JH, Jeong SH, Lee YB. Preparation and In Vitro/In Vivo Characterization of Polymeric Nanoparticles Containing Methotrexate to Improve Lymphatic Delivery. Int J Mol Sci. 2019;20(13).

Arafat M, Kirchhoefer C, Mikov M, Sarfraz M, Löbenberg R. Nanosized Liposomes Containing Bile Salt: A Vesicular Nanocarrier for Enhancing Oral Bioavailability of BCS Class III Drug. J Pharm Pharm Sci. 2017;20:305-18.

Chen G, Fawcett JP, Mikov M, Tucker IG. Monoketocholate can decrease transcellular permeation of methotrexate across Caco-2 cell monolayers and reduce its intestinal absorption in rat. J Pharm Pharmacol. 2009;61:953-9.

Kecman S et al. Potentials of human bile acids and their salts in pharmaceutical nano delivery and formulations adjuvants. Technol Health Care. 2019 Sep 17.

Parezanović GŠ et al. Environmental Transformation of Pharmaceutical Formulations: A Scientific Review. Arch Environ Contam Toxicol. 2019;77:155-61.

Ekinci M, Ilem-Ozdemir D, Gundogdu E, Asikoglu M. Methotrexate loaded chitosan nanoparticles: Preparation, radiolabeling and in vitro evaluation for breast cancer diagnosis. J Drug Deliv Sci Technol. 2015;30:107-13.

Pinto MF, Moura CC, Nunes C, Segundo MA, Costa Lima SA, Reis S. A new topical formulation for psoriasis: development of methotrexate-loaded nanostructured lipid carriers. Int J Pharm. 2014;477:519-26.

Ge X, Wei M, He S, Yuan WE. Advances of Non-Ionic Surfactant Vesicles (Niosomes) and Their Application in Drug Delivery. Pharmaceutics. 2019;11:55.

Abdelbary AA, AbouGhaly MH. Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: application of Box-Behnken design, in-vitro evaluation and in-vivo skin deposition study. Int J Pharm. 2015;485:235-43.

Abbasi MM, Monfaredan A, Hamishehkar H, Jahanban-Esfahlan R. New formulated "DOX-MTX-loaded nanoparticles" down- regulate HER2 gene expression and improve the clinical outcome in OSCCs model in rat: the effect of IV and oral modalities. Asian Pac J Cancer Prev. 2014;15:9355-60.

Jang JH, Jeong SH, Lee YB. Preparation and In Vitro/In Vivo Characterization of Polymeric Nanoparticles Containing Methotrexate to Improve Lymphatic Delivery. Int J Mol Sci. 2019;20(13).

Gebicki JM, Hicks M. Ufasomes are stable particles surrounded by unsaturated fatty acid membranes. Nature. 1973;243:232-4.

Sharma A, Arora S. Formulation and in vitro evaluation of ufasomes for dermal administration of methotrexate. ISRN Pharm. 2012;2012:873653.

Wohlrab J, Neubert RH, Michael J, Naumann S. Methotrexate for topical application in an extemporaneous preparation. J Dtsch Dermatol Ges. 2015;13:891-901.

Cintra GA. Bioadhesive Surfactant Systems for Methotrexate Skin Delivery. Molecules. 2016 Feb 18;21(2).